M. Tang

发表

Evaluation of the bioactivity of influenza vaccine strains in vitro suggests that the introduction of new strains in the 2010 Southern Hemisphere trivalent influenza vaccine is associated with adverse events.

M. Ng, S. Koernig, S. Rockman, 2014, Vaccine.

Repeat pneumococcal polysaccharide vaccine in Indigenous Australian adults is associated with decreased immune responsiveness.

J. Carapetis, A. Leach, S. Skull, 2017, Vaccine.

Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age.

Y. Cheung, J. Carapetis, E. Mulholland, 2011, Vaccine.

Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy.

Y. Cheung, J. Carapetis, E. Mulholland, 2010, Vaccine.

Serotype-specific avidity is achieved following a single dose of the 7-valent pneumococcal conjugate vaccine, and is enhanced by 23-valent pneumococcal polysaccharide booster at 12 months.

Y. Cheung, J. Carapetis, E. Mulholland, 2011, Vaccine.

Immunogenicity following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine.

Y. Cheung, J. Carapetis, E. Mulholland, 2009, Vaccine.

Antibodies to serotype 9V exhibit novel serogroup cross-reactivity following infant pneumococcal immunization.

E. Mulholland, F. Russell, P. Licciardi, 2010, Vaccine.

Immunogenicity for 16 serotypes of a unique schedule of pneumococcal vaccines in a high-risk population.

P. Morris, J. Carapetis, A. Leach, 2008, Vaccine.

Serotype-Specific Anti-Pneumococcal IgG and Immune Competence: Critical Differences in Interpretation Criteria When Different Methods are Used

P. Licciardi, A. Balloch, M. Tang, 2013, Journal of Clinical Immunology.

PneuMum: Impact from a randomised controlled trial of maternal 23-valent pneumococcal polysaccharide vaccination on middle ear disease amongst Indigenous infants, Northern Territory, Australia.

M. Chatfield, P. Morris, J. Carapetis, 2015, Vaccine.

Impaired serotype-specific immune function following pneumococcal vaccination in infants with prior carriage.

E. Mulholland, M. Nahm, G. Gilbert, 2014, Vaccine.

Impaired immune function following pneumococcal vaccination in infants with prior carriage

E. Mulholland, M. Nahm, F. Russell, 2014 .

Vaccine adjuvant properties of probiotic bacteria.

P. Licciardi, M. Tang, 2011, Discovery medicine.

Probiotic Therapy as a Novel Approach for Allergic Disease

P. Licciardi, Anzela Anzela, Z. Toh, 2012, Front. Pharmacol..

Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months of age, a randomized controlled trial.

Y. Cheung, J. Carapetis, E. Mulholland, 2010, Vaccine.

Results from an inter-laboratory comparison of pneumococcal serotype-specific IgG measurement and critical parameters that affect assay performance.

A. Leach, P. Licciardi, A. Nurkka, 2010, Vaccine.

The clinical syndrome of specific antibody deficiency in children.

R. Boyle, A. Balloch, M. Tang, 2006, Clinical and experimental immunology.

The clinical syndrome of specific antibody deficiency in children

A. Balloch, M. Tang, C. Le, 2006 .

Infants aged 12 months can mount adequate serotype-specific IgG responses to pneumococcal polysaccharide vaccine.

E. Mulholland, F. Russell, P. Licciardi, 2010, The Journal of allergy and clinical immunology.

Impact of the 23-valent pneumococcal polysaccharide vaccination in pregnancy against infant acute lower respiratory infections in the Northern Territory of Australia

R. Ware, P. Morris, J. Carapetis, 2018, Pneumonia.

Protocol_PneuMum_Final v3 9Feb2010

P. Morris, J. Carapetis, R. Andrews, 2010 .

Age-and serotype-dependent antibody response to pneumococcal polysaccharides Reply

E. Mulholland, F. Russell, P. Licciardi, 2011 .

Serotype-Specific Anti-Pneumococcal IgG and Immune Competence: Critical Differences in Interpretation Criteria When Different Methods are Used

P. Licciardi, A. Balloch, M. Tang, 2013, Journal of Clinical Immunology.

Pneumococcal polysaccharide vaccine at 12 months of age produces functional immune responses.

E. Mulholland, M. Nahm, R. Burton, 2012, The Journal of allergy and clinical immunology.